Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Passage BIO, Inc.PASG · Entity 7829 | Director | May 19, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Passage BIO, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2036-05-19 | Direct | 10,539 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 10,539 · Balance 10,539 F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2026 Filed May 21, 2026 20:14 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (right to buy) · Derivative | 10,539 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001986720-26-000002 · form4-05212026_080510.xml · derivative · entry 1 Sondhi Dolan · CIK 0001986720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,539 Underlying: Common Stock · 10,539 shares Expires 2036-05-19 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 23:27 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (right to buy) · Derivative | 201,857 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001415889-25-015055 · form4-05302025_110538.xml · derivative · entry 1 Sondhi Dolan · CIK 0001986720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,857 Underlying: Common Stock · 201,857 shares Expires 2035-05-28 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:52 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (right to buy) · Derivative | 39,092 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001415889-24-014310 · form4-05232024_080524.xml · derivative · entry 1 Sondhi Dolan · CIK 0001986720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,092 Underlying: Common Stock · 39,092 shares Expires 2034-05-21 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| July 27, 2023 Filed Jul 31, 2023 21:34 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (right to buy) · Derivative | 48,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001209191-23-043872 · doc4.xml · derivative · entry 1 Sondhi Dolan · CIK 0001986720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2033-07-27 F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares on August 28, 2023, and thereafter vests as to 1/36 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.